NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00310-0950-36 | 00310-0950 | Goserelin acetate | Zoladex | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 5, 2003 | May 31, 2020 | No Longer Used | |
00310-0951-30 | 00310-0951 | Goserelin acetate | Zoladex | 10.8 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 5, 2003 | March 31, 2020 | No Longer Used | |
50090-3466-00 | 50090-3466 | Goserelin acetate | ZOLADEX | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 30, 2018 | In Use | ||
70720-0950-36 | 70720-0950 | Goserelin | ZOLADEX | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | March 31, 2018 | In Use | ||
70720-0951-30 | 70720-0951 | Goserelin | ZOLADEX | 10.8 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 26, 2018 | In Use | ||
50633-0210-11 | 50633-0210 | Glucarpidase | Voraxaze | 1000.0 [USP'U]/1 | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | April 1, 2012 | In Use | |
50242-0125-01 | 50242-0125 | Glofitamab | Columvi | 2.5 mg/2.5mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | June 15, 2023 | In Use | |
50242-0127-01 | 50242-0127 | Glofitamab | Columvi | 10.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | June 15, 2023 | In Use | |
00069-0298-60 | 00069-0298 | Glasdegib | Daurismo | 25.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec. 10, 2018 | In Use | |
00069-1531-30 | 00069-1531 | Glasdegib | Daurismo | 100.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec. 10, 2018 | In Use | |
00469-1425-21 | 00469-1425 | Gilteritinib | Xospata | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 30, 2022 | In Use | |
00469-1425-90 | 00469-1425 | Gilteritinib | Xospata | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Nov. 29, 2018 | In Use | |
00008-4510-01 | 00008-4510 | Gemtuzumab ozogamicin | Mylotarg | 5.0 mg/5mL | Immunotherapy | Drug Antibody Conjugate | CD33 | Intravenous | Sept. 7, 2017 | In Use | |
00002-7502-01 | 00002-7502 | Gemcitabine hydrochloride | Gemzar | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 22, 1996 | In Use | |
71288-0117-06 | 71288-0117 | Gemcitabine hydrochloride | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 11, 2020 | In Use | |
71288-0117-28 | 71288-0117 | Gemcitabine hydrochloride | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 11, 2020 | In Use | |
71288-0117-54 | 71288-0117 | Gemcitabine hydrochloride | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 11, 2020 | In Use | |
00002-7501-01 | 00002-7501 | Gemcitabine hydrochloride | Gemzar | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 22, 1996 | May 31, 2020 | No Longer Used |
55390-0391-10 | 55390-0391 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 40.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 19, 2012 | In Use | |
55390-0391-50 | 55390-0391 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 40.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 19, 2012 | In Use | |
68083-0148-01 | 68083-0148 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 1, 2016 | In Use | |
68083-0149-01 | 68083-0149 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 1, 2016 | In Use | |
16714-0909-01 | 16714-0909 | Gemcitabine Hydrochloride | Gemcitabine | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov. 1, 2018 | In Use | |
25021-0209-50 | 25021-0209 | Gemcitabine Hydrochloride | Gemcitabine | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 25, 2011 | July 31, 2017 | No Longer Used |
25021-0234-10 | 25021-0234 | Gemcitabine Hydrochloride | gemcitabine | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 29, 2014 | In Use |
Found 10,000 results in 14 milliseconds — Export these results